Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas

Table 2

Dynamic contrast enhanced CT attenuation (HU) of all subtypes of renal cell carcinoma.

	Xp11.2 RCC ( = 25)	PRCC ( = 37)	Type 1 PRCC ( = 12)	Type 2 PRCC ( = 25)
Unenhanced phase	44.8 ± 11.2	39.8 ± 6.6	38.9 ± 6.3	40.2 ± 6.8	0.032
Corticomedullary phase	81.3 ± 41.0	66.0 ± 31.9	56.0 ± 16.7	70.8 ± 36.4	0.114
Nephrographic phase	93.1 ± 40.0	73.1 ± 20.0	71.4 ± 17.4	73.8 ± 21.4	0.021
Delayed phase	80.3 ± 32.5	66.7 ± 25.6	56.8 ± 18.9	72.3 ± 35.7	0.126

Notes: Xp11.2 RCC: renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions; PRCC: papillary renal cell carcinoma; (Xp11.2 RCC versus PRCC).